Samsung Bioepis has gained government clearance to begin a phase 3 clinical trial of its ranibizumab biosimilar in the Republic of Korea.
Samsung Bioepis has gained government clearance to begin a phase 3 clinical trial of its ranibizumab biosimilar in the Republic of Korea.
According to Korea Biomedical Review, the Korean Ministry of Food and Drug Safety (MFDS) has approved the company’s phase 3 clinical trial for SB11, a biosimilar product referencing Roche’s Lucentis, which is approved to treat neovascular age-related macular degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. The multi-center domestic trial will comprise 140 patients who have AMD.
Samsung Bioepis is not alone in seeking a share of the market for Lucentis; US-based Pfenex and the German company Formycon are also developing biosimilar ranibizumab.
This week, Samsung Bioepis also gained MFDS approval to sell its adalimumab biosimilar, SB5, in the Republic of Korea. Samsung Bioepis gained a marketing authorization for the same drug, referenced on AbbVie’s blockbuster Humira, from the European Commission (EC) on August 24, 2017. The company plans to sell its biosimilar as Imraldi in the European Union.
News of Samsung Bioepis’ ranibizumab trial and adalimumab approval follow last week’s progress for its biosimilar trastuzumab, SB3, referenced on Herceptin. On Friday, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion of the drug.
On EC clearance, Samsung Bioepis plans to market the drug under the name Ontruzant. In order to ensure a reliable supply of the trastuzumab treatment, the company plans to partner with multiple contracting organizations to carry out production of Ontruzant, a Samsung representative said.
Meanwhile, the biosimilar developer fended off rumors of a split with its marketing and distribution partner, MSD, in the Korean market. The Investor says that representatives from Samsung Bioepis today denied reports that a drug licensing agreement with MSD for Brenzys (a biosimilar etanercept, referenced on Enbrel) and Renflexis (a biosimilar infliximab, referenced on Remicade) had terminated after disappointing sales of the 2 biosimilars. According to The Investor, the cost savings provided by biosimilar therapies in the Korean marketplace typically do not exceed 10%, and have not produced rapid sales.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.